Human senescent cell atlas across the lifespan

Developing StoryLast updated
SUMMARY

The NIH Common Fund's Cellular Senescence Network (SenNet) released the first comprehensive atlas of human senescent cells across various body tissues on July 17, 2026, introducing 'senotypes' and identifying new blood biomarkers for kidney disease, frailty, and diabetes risk. As of July 20, 2026: The atlas, published in *Cell*, is actively informing clinical trials for senolytic and senomorphic therapies, with ongoing validation of cell markers. Fisetin, a natural flavonoid, is being explored for its potential to target senescent cells, aligning with the "precision senescence" approach. The atlas continues to integrate new tissue datasets to differentiate between harmful and beneficial senescent states.

Timeline

Want updates on this thread?

Track this story

July 2026 — 5 developments

  1. Fisetin Explored for Targeted Senescent Cell Therapy Following Senescent Cell Atlas Development

    Fisetin, a natural flavonoid, is being explored for its potential to target senescent cells, aligning with the "precision senescence" approach developed by the SenNet consortium. This research aims to leverage the understanding gained from the senescent cell atlas to develop targeted therapies for age-related diseases.

  2. NIH Releases First Comprehensive Atlas of Senescent Cells in Human Tissues

    The NIH Common Fund's Cellular Senescence Network (SenNet) has released the first comprehensive atlas of senescent cells across various human body tissues, introducing a new classification system called 'senotypes.' This atlas maps senescent cells and identifies new biomarkers in the blood that can predict kidney disease, frailty, and future diabetes risk. The research was published in the journal *Cell*.

  3. Human Senescent Cell Atlas Informs Clinical Trials for Senolytic and Senomorphic Therapies

    The insights generated by the Human Senescent Cell Atlas are actively informing the design and execution of clinical trials for novel senolytic and senomorphic therapies. These trials aim to test interventions that specifically target senescent cells to improve health outcomes and combat age-related diseases.

  4. Validation of Senescent Cell Markers Remains Critical Focus for Atlas Project

    Ongoing validation of cell markers for senescent cells remains a critical focus within the atlas project. Continuous efforts are dedicated to ensuring the robustness, reliability, and specificity of detection methods across diverse human tissues and experimental conditions, which is vital for accurate mapping.

  5. NIH-Supported Human Senescent Cell Atlas Continues Development, Integrating New Data

    The NIH-supported Human Senescent Cell Atlas continues its active development, integrating new tissue datasets and refining the comprehensive characterization of senescent cells across the human lifespan. A primary objective remains to differentiate between harmful and potentially beneficial senescent states to guide therapeutic strategies.

December 2025 — 1 developments

  1. Human Senescent Cell Atlas Identifies Promising New Drug Targets for Therapies

    The comprehensive data from the atlas facilitated the identification of promising new drug targets based on the detailed molecular profiles of senescent cells. This work focuses on pinpointing specific pathways that could be selectively modulated or targeted for the development of novel therapeutic interventions.

June 2025 — 1 developments

  1. Atlas Insights Inform New Hypotheses on Senescent Cell Mechanisms in Aging and Disease

    Preliminary insights derived from the developing Human Senescent Cell Atlas began to inform new hypotheses regarding the precise mechanisms by which senescent cells contribute to the aging process and the progression of various diseases. These insights are crucial for guiding future research directions.

December 2024 — 1 developments

  1. SenNet Develops Advanced AI and Machine Learning for High-Resolution Atlas Construction

    Computational biologists within the SenNet consortium developed and deployed advanced machine learning and artificial intelligence algorithms. These sophisticated tools are critical for analyzing the vast and complex single-cell and spatial transcriptomics data generated, enabling the construction of a high-resolution senescent cell atlas.

June 2024 — 1 developments

  1. SenNet Expands Tissue Mapping to Include Diverse Tissue Types and Disease Samples

    SenNet significantly expanded its tissue mapping efforts, incorporating a broader array of tissue types and samples from individuals with specific age-related diseases. This expansion aims to deepen the understanding of how senescence contributes to various pathological contexts and its role in disease progression.

December 2023 — 1 developments

  1. SenNet Analyses Reveal Heterogeneity of Senescent Cells and Potential Diverse Roles

    Early analyses emerging from the SenNet program began to shed light on the significant heterogeneity of senescent cells. This research aims to understand that not all senescent cells are identical, and they may possess distinct functional roles, with some potentially exhibiting beneficial effects in certain contexts.

June 2023 — 1 developments

  1. SenNet Researchers Validate Existing and Identify Novel Senescent Cell Markers

    Researchers within the SenNet program commenced rigorous validation of existing senescent cell markers while actively working to identify novel ones. This critical effort aims to enhance the accuracy, specificity, and reliability of senescent cell detection across the wide array of human tissues being studied.

January 2023 — 1 developments

  1. SenNet Releases First Public Data on Senescent Cell Markers and Tissue Distribution

    SenNet achieved a significant milestone by releasing its first public data, making preliminary datasets on senescent cell markers and their distribution in select tissues accessible to the broader scientific community. This initial release included detailed methodologies and early findings, fostering collaborative research.

September 2022 — 1 developments

  1. SenNet Begins Collection of Diverse Human Tissue Samples for Atlas Foundation

    Initial efforts within the SenNet program focused on the systematic collection of diverse human tissue samples from a wide range of donors. These samples encompassed varying ages, sexes, and health conditions, forming the foundational dataset necessary for constructing a comprehensive and representative senescent cell atlas.

March 2022 — 1 developments

  1. SenNet Develops Standardized Protocols for Senescent Cell Identification and Tissue Processing

    SenNet initiated the crucial process of developing standardized protocols for tissue collection, processing, and the precise identification of senescent cells. These standardized methods are essential to ensure data consistency, comparability, and reliability across all participating research sites within the network.

October 2021 — 2 developments

  1. Yale University Joins SenNet Program, Contributing Single-Cell Genomics Expertise

    Yale University officially joined the SenNet program, bringing its specialized expertise in single-cell genomics and computational biology to the consortium. Yale's involvement is critical for developing and applying advanced analytical methods to process and interpret the vast amounts of data generated for the senescent cell atlas.

  2. University of Pittsburgh and UPMC Secure $12.5M NIH Grant for SenNet Tissue Mapping Center

    The University of Pittsburgh and UPMC received a substantial $12.5 million grant from the NIH Common Fund as part of the SenNet program. This funding was allocated to establish a dedicated Tissue Mapping Center, focusing on the crucial task of collecting and analyzing human tissue samples to identify and characterize senescent cells.

September 2021 — 2 developments

  1. SenNet Establishes Initial Network of Research and Data Coordinating Centers

    Following its launch, the SenNet program established an initial network of research centers and data coordinating centers across the United States. These centers, involving multiple institutions, were tasked with systematically collecting and analyzing diverse senescent cell data to build the foundational atlas.

  2. NIH Common Fund Launches Cellular Senescence Network (SenNet) Program

    The National Institutes of Health (NIH) Common Fund officially launched the Cellular Senescence Network (SenNet) program. This major initiative aims to create a comprehensive atlas of senescent cells, mapping their presence and characteristics across human tissues, ages, and various disease states to understand their roles in health and disease.

January 2018 — 1 developments

  1. NIH Common Fund Embraces Large-Scale Multi-Omics Research Approaches

    The NIH Common Fund began to emphasize large-scale, multi-omics approaches to understand complex biological processes, exemplified by programs like the Molecular Transducers of Physical Activity Consortium (MoTrPAC). This strategic shift laid the groundwork for future comprehensive mapping initiatives, including the SenNet program.

January 2015 — 1 developments

  1. First Senolytic Drugs Discovered, Paving Way for New Age-Related Therapies

    A significant breakthrough occurred with the discovery of the first senolytic drugs, compounds capable of selectively eliminating senescent cells. This development demonstrated the feasibility of targeting senescent cells for therapeutic purposes, opening new avenues for treating age-related diseases.

January 2008 — 1 developments

  1. Discovery of Senescence-Associated Secretory Phenotype Reveals Active Role of Senescent Cells

    Researchers discovered the Senescence-Associated Secretory Phenotype (SASP), a critical finding that revealed senescent cells are not merely inert but actively secrete a complex mixture of inflammatory molecules. This discovery highlighted how senescent cells can impact surrounding tissues and contribute to age-related pathologies.

January 1997 — 1 developments

  1. Key Molecular Markers Like p16INK4a Gain Recognition for Senescent Cell Identification

    The scientific community increasingly recognized key molecular markers, such as p16INK4a, as crucial tools for identifying and studying senescent cells. These markers provided a more precise way to detect senescent cells in tissues, advancing the understanding of their role in aging and disease.

January 1965 — 1 developments

  1. Leonard Hayflick Formally Names 'Cellular Senescence' as Key Aging Process

    Building on his earlier work, Leonard Hayflick formally named the state of irreversible growth arrest in cells as 'cellular senescence.' This naming provided a clear definition for the phenomenon and established it as a distinct biological process relevant to aging.

January 1961 — 1 developments

  1. Hayflick and Moorhead Discover Finite Cell Division, Laying Groundwork for Senescence

    Leonard Hayflick and Paul Moorhead made a groundbreaking discovery, demonstrating that human cells have a finite capacity for division in vitro. This phenomenon, known as the Hayflick limit, laid the foundational understanding for cellular aging and the concept of senescence.